Dr. Vijayabhanu Mahadevan, MD

Dr. Mahadevan practices at American Arthritis & Rheumatology Associates AZ P in Surprise, Arizona.

Dr. Mahadevan's NPI, 1083727333, was assigned on August 17, 2006. Dr. Mahadevan holds Arizona license 37475.

Dr. Mahadevan's primary practice is American Arthritis & Rheumatology Associates AZ P, at 12665 W Smokey Dr, Surprise, AZ 85378 in Maricopa County. The practice phone is (623) 219-4040.

Dr. Mahadevan's primary practice is American Arthritis & Rheumatology Associates AZ P in Surprise, Arizona. Dr. Mahadevan is also affiliated with Banner Thunderbird Medical Center. The medical group on file is NovaCare Rehabilitation. Dmand AI also links Dr. Mahadevan to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahadevan practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Mahadevan's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Dr. Mahadevan's licenses on file in 2 states: Arizona and Virginia.

CMS data shows 223,410 Medicare services from Dr. Mahadevan across 34 procedure codes in 2024, for 1,021 Medicare patients. Medicare paid $2,452,171 for them. Every service was in an office.

CMS counts 1,021 Medicare patients who saw Dr. Mahadevan in 2024. The largest group is 75 to 84, with 508 patients. 75% of them have arthritis, and 75% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mahadevan's median patient age at 73, with 80% women.

In 2024, Dr. Mahadevan wrote 5,533 Medicare Part D claims for 1,017 patients. 89% of them were for generic drugs. CMS names the drug for 5,297 of them, across 40 drugs with 11 or more claims each, at $2,639,821 in total drug cost. In 2023, CMS named 4,954 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Mahadevan for performance year 2024, reported as part of a group. Dr. Mahadevan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mahadevan as offering telehealth.

CMS Open Payments shows 653 general payments to Dr. Mahadevan from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Abbvie Inc. paid the most, $11,638. It also lists 2 research payments totaling $2,146 in 2016.